ACRS vs HY Comparison

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Hyster Yale Inc designs, engineers, manufactures, sells, and services a comprehensive line of lift trucks, attachments, aftermarket parts, and technology solutions marketed globally under the Hyster and Yale brand names. The company has four segments, which include three in the lift truck business as discussed below, as well as Bolzoni S.p.A. (Bolzoni). The majority of its revenue is generated from Lift Trucks. Geographically, it operates in America, EMEA, and JAPIC regions, of which maximum revenue is generated from its business in America, which includes lift truck operations in the U.S., Canada, Mexico, Brazil, and Latin America.